RVTY · Revvity, Inc.

These shares are being surrendered to satisfy a tax withholding obligation upon vesting of restricted stock units originally granted on June 15, 2023, as required by the Reporting Person's Restricted Stock Unit Agreement.

The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control.

Includes shares related to dividends on shares in the Reporting Person's Deferred Compensation Plan account.

The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control.

The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control.

The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control.

The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control.

The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control.

The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control.

The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control.

The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control.

Includes shares related to dividends on shares in the Reporting Person's Deferred Compensation Plan account.

The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025.

Shares are time-based restricted stock units that are scheduled to fully vest on the second anniversary of the date of grant.

This option is scheduled to fully vest on the second anniversary of the date of grant.

This option is scheduled to vest in three equal installments on February 15, 2027, February 15, 2028, and February 15, 2029.

Shares are time-based restricted stock units that are scheduled to vest in three equal installments on February 15, 2027, February 15, 2028, and February 15, 2029.

This option became exercisable in three equal annual installments beginning on March 1, 2020, which was the first anniversary of the date on which the option was granted.

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 26, 2025.

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 26, 2025.

The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $97.15 to $97.35. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

These shares are being surrendered to satisfy a tax withholding obligation upon vesting of restricted stock originally granted on February 16, 2023, as required by the Reporting Person's Restricted Stock Agreement.

These shares are being surrendered to satisfy a tax withholding obligation upon vesting of restricted stock units originally granted on March 1, 2024, as required by the Reporting Person's Restricted Stock Unit Agreement.

These shares are being surrendered to satisfy a tax withholding obligation upon vesting of restricted stock units originally granted on February 16, 2023, as required by the Reporting Person's Restricted Stock Unit Agreement.

These shares are being surrendered to satisfy a tax withholding obligation upon vesting of restricted stock units originally granted on March 21, 2025, as required by the Reporting Person's Restricted Stock Unit Agreement.

These shares are being surrendered to satisfy a tax withholding obligation upon vesting of restricted stock originally granted on February 16, 2023, as required by the Reporting Person's Restricted Stock Agreement.

These shares are being surrendered to satisfy a tax withholding obligation upon vesting of restricted stock units originally granted on March 3, 2023, as required by the Reporting Person's Restricted Stock Unit Agreement.

These shares are being surrendered to satisfy a tax withholding obligation upon vesting of restricted stock originally granted on February 16, 2023, as required by the Reporting Person's Restricted Stock Agreement.

These shares are being surrendered to satisfy a tax withholding obligation upon vesting of restricted stock originally granted on February 16, 2023, as required by the Reporting Person's Restricted Stock Agreement.

These shares are being surrendered to satisfy a tax withholding obligation upon vesting of restricted stock originally granted on February 16, 2023, as required by the Reporting Person's Restricted Stock Agreement.

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 6, 2025.

The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $100.98 to $101.93. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 6, 2025.

The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $101.12 to $101.93. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 6, 2025.

The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $99.10 to $100.08. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

This option became exercisable in three equal annual installments beginning on February 5, 2020, which was the first anniversary of the date on which the option was granted.

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 6, 2025.

The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $98.98 to $99.07. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 6, 2025.

The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $98.98 to $99.97. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 6, 2025.

The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $99.98 to $100.95. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

This option became exercisable in three equal annual installments beginning on February 5, 2020, which was the first anniversary of the date on which the option was granted.

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 6, 2025.

The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $102.18 to $103.03. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 6, 2025.

The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $100.10 to $101.09. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 6, 2025.

The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $102.18 to $103.03. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.